Eurointervention最新文献

筛选
英文 中文
The challenge of interpreting comparative TAVI studies. 解释比较TAVI研究的挑战。
IF 7.6 1区 医学
Eurointervention Pub Date : 2025-07-07 DOI: 10.4244/EIJ-E-25-00028
Liesbeth Rosseel, Arif A Khokhar, Ole De Backer
{"title":"The challenge of interpreting comparative TAVI studies.","authors":"Liesbeth Rosseel, Arif A Khokhar, Ole De Backer","doi":"10.4244/EIJ-E-25-00028","DOIUrl":"10.4244/EIJ-E-25-00028","url":null,"abstract":"","PeriodicalId":54378,"journal":{"name":"Eurointervention","volume":"21 13","pages":"e718-e719"},"PeriodicalIF":7.6,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12207333/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144585673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The new balloon-expandable Myval transcatheter heart valve: only good news? 新型球囊可扩张Myval经导管心脏瓣膜:只有好消息吗?
IF 7.6 1区 医学
Eurointervention Pub Date : 2025-07-07 DOI: 10.4244/EIJ-E-25-00024
Philippe Pibarot, Eric Van Belle
{"title":"The new balloon-expandable Myval transcatheter heart valve: only good news?","authors":"Philippe Pibarot, Eric Van Belle","doi":"10.4244/EIJ-E-25-00024","DOIUrl":"10.4244/EIJ-E-25-00024","url":null,"abstract":"","PeriodicalId":54378,"journal":{"name":"Eurointervention","volume":"21 13","pages":"e720-e722"},"PeriodicalIF":7.6,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12207331/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144585674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A comparison of antiplatelet and oral anticoagulation strategies to prevent cerebral microembolism after transcatheter aortic valve implantation: the AUREA trial. 经导管主动脉瓣植入术后抗血小板和口服抗凝策略预防脑微栓塞的比较:AUREA试验
IF 7.6 1区 医学
Eurointervention Pub Date : 2025-07-07 DOI: 10.4244/EIJ-D-24-00872
Victor Alfonso Jimenez Diaz, Pablo Juan-Salvadores, Paula Bellas Lamas, Mercedes Arias Gonzalez, Eloisa Santos Armentia, Oscar Vila Nieto, Carmen Gonzalez Mao, Tamara Torrado Chedas, Antonio Jesus Muñoz Garcia, Ivan Gomez Blazquez, Guillermo Bastos Fernandez, Antonio De Miguel Castro, Saleta Fernandez Barbeira, Alberto Ortiz Saez, Jose Antonio Baz Alonso, Juan Ocampo Miguez, Lucia Rioboo Leston, Pablo Pazos Lopez, Francisco Calvo Iglesias, Angel Salgado Barreira, Carlos Maria Diaz Lopez, Adolfo Figueiras, Cesar Veiga Garcia, Andres Iñiguez Romo
{"title":"A comparison of antiplatelet and oral anticoagulation strategies to prevent cerebral microembolism after transcatheter aortic valve implantation: the AUREA trial.","authors":"Victor Alfonso Jimenez Diaz, Pablo Juan-Salvadores, Paula Bellas Lamas, Mercedes Arias Gonzalez, Eloisa Santos Armentia, Oscar Vila Nieto, Carmen Gonzalez Mao, Tamara Torrado Chedas, Antonio Jesus Muñoz Garcia, Ivan Gomez Blazquez, Guillermo Bastos Fernandez, Antonio De Miguel Castro, Saleta Fernandez Barbeira, Alberto Ortiz Saez, Jose Antonio Baz Alonso, Juan Ocampo Miguez, Lucia Rioboo Leston, Pablo Pazos Lopez, Francisco Calvo Iglesias, Angel Salgado Barreira, Carlos Maria Diaz Lopez, Adolfo Figueiras, Cesar Veiga Garcia, Andres Iñiguez Romo","doi":"10.4244/EIJ-D-24-00872","DOIUrl":"10.4244/EIJ-D-24-00872","url":null,"abstract":"<p><strong>Background: </strong>The effectiveness of oral anticoagulation (OAC) or dual antiplatelet therapy (DAPT) in reducing subclinical brain infarcts after transcatheter aortic valve implantation (TAVI) remains unclear.</p><p><strong>Aims: </strong>We aimed to compare the efficacy of DAPT versus OAC in preventing cerebral microembolism during the first 3 months post-TAVI, assessed by diffusion-weighted magnetic resonance imaging (DW-MRI).</p><p><strong>Methods: </strong>Patients with aortic stenosis and no indication for OAC were randomly assigned to receive either OAC (acenocoumarol) or DAPT (aspirin+clopidogrel) for 3 months post-TAVI. Brain DW-MRI was performed at baseline (0-3 days pre-TAVI) and at 6 and 90 days post-TAVI. The primary objective was the proportion of patients with new cerebral emboli on DW-MRI at 6 and 90 days.</p><p><strong>Results: </strong>Of the 123 patients included in the study, 3.3% had new cerebral emboli on the baseline MRI prior to TAVI. At 6 days post-TAVI, new cerebral emboli were observed in 81.4% of OAC patients versus 69.8% of DAPT patients (p=0.209), and at 90 days, in 8.0% versus 8.2%, respectively (p=0.879). However, DAPT patients had a lower mean total emboli volume at 6 days (265.9 mm³ vs 303.4 mm³; p=0.019) and cumulatively at 6+90 days (266.45 mm³ vs 331.10 mm³; p=0.008).</p><p><strong>Conclusions: </strong>In patients without an indication for OAC, an OAC strategy for 3 months post-TAVI did not show any benefit over an antiplatelet strategy in preventing cerebral microembolism. Patients treated with DAPT showed a lower mean volume of brain damage on DW-MRI during the 90 days following TAVI compared to those treated with acenocoumarol.</p>","PeriodicalId":54378,"journal":{"name":"Eurointervention","volume":"21 13","pages":"e737-e748"},"PeriodicalIF":7.6,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12230756/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144585665","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Four-year durability of the Myval balloon-expandable transcatheter aortic valve. Myval球囊可扩张经导管主动脉瓣的四年耐久性。
IF 7.6 1区 医学
Eurointervention Pub Date : 2025-07-07 DOI: 10.4244/EIJ-D-24-01112
Akash Jain, John Jose, Matteo Montorfano, Henrik Nissen, Pedro Martin, Ashok Seth, Kresimir Stambuk, Gunasekaran Sengottuvelu, Mussayev Abdurashid, Mario García-Gómez, Clara Fernandez-Cordón, Marcelo Rodriguez, Mathias D Jorgensen, Alberto Campo, Ana Serrador, Silvia Vallinas-Hernandez, Manuel Carrasco-Moraleja, Alberto San Román, Ignacio J Amat-Santos
{"title":"Four-year durability of the Myval balloon-expandable transcatheter aortic valve.","authors":"Akash Jain, John Jose, Matteo Montorfano, Henrik Nissen, Pedro Martin, Ashok Seth, Kresimir Stambuk, Gunasekaran Sengottuvelu, Mussayev Abdurashid, Mario García-Gómez, Clara Fernandez-Cordón, Marcelo Rodriguez, Mathias D Jorgensen, Alberto Campo, Ana Serrador, Silvia Vallinas-Hernandez, Manuel Carrasco-Moraleja, Alberto San Román, Ignacio J Amat-Santos","doi":"10.4244/EIJ-D-24-01112","DOIUrl":"10.4244/EIJ-D-24-01112","url":null,"abstract":"<p><strong>Background: </strong>The Myval series is the first commercially available balloon-expandable transcatheter aortic valve implantation (TAVI) system designed as an alternative to the SAPIEN series. The LANDMARK trial recently demonstrated its non-inferiority compared to contemporary systems. However, the long-term durability of the Myval series remains unknown.</p><p><strong>Aims: </strong>We aimed to evaluate the 4-year durability of the Myval series using Valve Academic Research Consortium (VARC)-3-defined endpoints.</p><p><strong>Methods: </strong>We carried out a multicentre ambispective study of patients with severe aortic stenosis who underwent TAVI with the Myval series between December 2017 and April 2020. Baseline characteristics were prospectively recorded in a dedicated database. Clinical and echocardiographic follow-up was performed at 4 years. Outcomes included haemodynamic valve deterioration (HVD), bioprosthetic valve failure (BVF), and patient-prosthesis mismatch (PPM) as defined by the VARC-3 criteria, assessed at a central echocardiography laboratory.</p><p><strong>Results: </strong>A total of 366 patients from 9 institutions were included, all of whom completed 4-year follow-up or were followed up until death. The 4-year survival rate was 81.8%, with residual ≥moderate aortic regurgitation observed in 9.2% of patients. BVF criterion 1 (symptomatic valve failure) occurred in 3.3%, while no cases of BVF criteria 2 or 3 were reported. Stage 2 HVD was observed in 9.7% of patients and stage 3 HVD in 0.7% at 4 years. Moderate and severe PPM were identified in 3.6% and 2.1% of patients at 1 year, respectively.</p><p><strong>Conclusions: </strong>In a real-world cohort, 4-year outcomes with the balloon-expandable Myval series demonstrated acceptable valve durability, low haemodynamic deterioration, and comparable performance to contemporary TAVI systems.</p>","PeriodicalId":54378,"journal":{"name":"Eurointervention","volume":"21 13","pages":"e758-e765"},"PeriodicalIF":7.6,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12207338/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144585669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reply: Completeness or complexity? A nuanced reflection on multivessel revascularisation. 回复:完整性还是复杂性?对多血管重建的细致反映。
IF 7.6 1区 医学
Eurointervention Pub Date : 2025-06-16 DOI: 10.4244/EIJ-D-25-00325
Claudio Laudani, Giovanni Occhipinti, Antonio Greco, Marco Spagnolo, Daniele Giacoppo, Davide Capodanno
{"title":"Reply: Completeness or complexity? A nuanced reflection on multivessel revascularisation.","authors":"Claudio Laudani, Giovanni Occhipinti, Antonio Greco, Marco Spagnolo, Daniele Giacoppo, Davide Capodanno","doi":"10.4244/EIJ-D-25-00325","DOIUrl":"10.4244/EIJ-D-25-00325","url":null,"abstract":"","PeriodicalId":54378,"journal":{"name":"Eurointervention","volume":"21 12","pages":"e713-e714"},"PeriodicalIF":7.6,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12151159/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144303602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Antithrombotic drugs for acute coronary syndromes in women: sex-adjusted treatment and female representation in randomised clinical trials. A clinical consensus statement of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) and the ESC Working Group on Thrombosis. 抗血栓药物治疗女性急性冠状动脉综合征:性别调整治疗和随机临床试验中的女性代表欧洲经皮心血管干预协会(EAPCI)和ESC血栓工作组的临床共识声明。
IF 9.5 1区 医学
Eurointervention Pub Date : 2025-06-16 DOI: 10.4244/EIJ-D-24-00876
Valeria Paradies, Giulia Masiero, Andrea Rubboli, Heleen M M Van Beusekom, Francesco Costa, Piera Capranzano, Sophie Degrauwe, Diana A Gorog, Claudia Moreira Jorge, Gill Louise Buchanan, Mirvat Alasnag, Daniela Trabattoni, Chiara Fraccaro, Dirk Sibbing, Dariusz Dudek, Gemma Vilahur, Alaide Chieffo, Roxana Mehran, Davide Capodanno, Emanuele Barbato, Jolanta M Siller-Matula
{"title":"Antithrombotic drugs for acute coronary syndromes in women: sex-adjusted treatment and female representation in randomised clinical trials. A clinical consensus statement of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) and the ESC Working Group on Thrombosis.","authors":"Valeria Paradies, Giulia Masiero, Andrea Rubboli, Heleen M M Van Beusekom, Francesco Costa, Piera Capranzano, Sophie Degrauwe, Diana A Gorog, Claudia Moreira Jorge, Gill Louise Buchanan, Mirvat Alasnag, Daniela Trabattoni, Chiara Fraccaro, Dirk Sibbing, Dariusz Dudek, Gemma Vilahur, Alaide Chieffo, Roxana Mehran, Davide Capodanno, Emanuele Barbato, Jolanta M Siller-Matula","doi":"10.4244/EIJ-D-24-00876","DOIUrl":"10.4244/EIJ-D-24-00876","url":null,"abstract":"<p><p>Thrombotic and bleeding risks differ between sexes, partly in relation to distinct biology and hormonal status, but also due to differences in age, comorbidities, and body size at presentation. Women experience frequent fluctuations of prothrombotic and bleeding status related to menstrual cycle, use of oral contraceptives, hormone replacement therapy, or menopause. Although clinical studies tend to underrepresent women, available data consistently support sex-specific differences in the baseline thrombotic and haemorrhagic risks. Compared with men, women feature an increased risk of in-hospital bleeding related to invasive procedures, as well as long-term out-of-hospital bleeding events. In addition, the inappropriate dosing of antithrombotic drugs, which is not adapted to body weight or renal function, is more frequently associated with an increased risk of bleeding in women compared to men. While acute coronary syndrome (ACS) studies support similar antithrombotic drug efficacy, irrespective of sex, women may receive delayed treatment due to bias in their referral, diagnosis, and invasive treatment decisions. The current clinical consensus statement highlights the need for an increased awareness of sex-specific risks and biases in ACS management, with a focus on sex-specific bleeding mitigation strategies, antithrombotic management in special conditions (e.g., myocardial infarction with non-obstructive coronary arteries), and barriers to female representation in cardiovascular trials. This manuscript aims to provide expert opinion, based on the best available evidence, and consensus statements on optimising antithrombotic therapy according to sex, which is critical to improve sex-based disparities in outcome.</p>","PeriodicalId":54378,"journal":{"name":"Eurointervention","volume":" ","pages":"e655-e667"},"PeriodicalIF":9.5,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12151167/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144095886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Chimney stenting for preventing coronary obstruction in redo-TAVI with balloon-expandable valves within self-expanding valves. 自膨胀瓣膜内装有球囊可膨胀瓣膜的血管支架置入术预防冠状动脉阻塞。
IF 7.6 1区 医学
Eurointervention Pub Date : 2025-06-16 DOI: 10.4244/EIJ-D-24-01018
Alessandro Beneduce, Arif A Khokhar, Jonathan Curio, Francesco Giannini, Adriana Zlahoda-Huzior, Won-Keun Kim, Francesco Maisano, Ole De Backer, Dariusz Dudek
{"title":"Chimney stenting for preventing coronary obstruction in redo-TAVI with balloon-expandable valves within self-expanding valves.","authors":"Alessandro Beneduce, Arif A Khokhar, Jonathan Curio, Francesco Giannini, Adriana Zlahoda-Huzior, Won-Keun Kim, Francesco Maisano, Ole De Backer, Dariusz Dudek","doi":"10.4244/EIJ-D-24-01018","DOIUrl":"10.4244/EIJ-D-24-01018","url":null,"abstract":"<p><strong>Background: </strong>Coronary obstruction (CO) is a major concern in redo-transcatheter aortic valve implantation (TAVI) for failing supra-annular self-expanding transcatheter aortic valves (TAVs).</p><p><strong>Aims: </strong>This ex vivo study tested chimney stenting (ChS) for redo-TAVI in patients with high-risk anatomy for CO by evaluating stent outcomes and the feasibility of subsequent coronary access (CA) for percutaneous coronary intervention (PCI).</p><p><strong>Methods: </strong>Patient-specific anatomical models were three-dimensionally printed from pre-TAVI computed tomography (CT) scans. Index TAVI was performed using ACURATE neo2 (ACn2) or Evolut PRO (EvPRO) with varying degrees of commissural misalignment (CMA). Redo-TAVI with bilateral ChS was performed in a pulsatile flow simulator using the balloon-expandable SAPIEN 3 Ultra (S3U) at different implant depths. Stent expansion was measured by intravascular ultrasound. Stent interactions and distortion angles were assessed by micro-CT. CA for PCI was attempted subsequently.</p><p><strong>Results: </strong>In the tested redo-TAVI combinations, interactions with index TAV frames or the aortic wall caused chimney stent distortion and underexpansion. A high S3U implant within an EvPRO resulted in the greatest stent underexpansion (complete crush) and vertical distortion (up to 75°). Severe CMA of the index TAV resulted in the greatest lateral stent distortion (up to 41° for ACn2 and 53° for EvPRO). The combination of CMA of the index TAV and a high S3U implant rendered CA and PCI after ChS unfeasible in 75% of cases.</p><p><strong>Conclusions: </strong>ChS during redo-TAVI with the S3U within a degenerated ACn2 or EvPRO valve is susceptible to interactions between the coronary stent and the TAV frames or the aortic wall, leading to stent distortion and underexpansion, which might compromise procedural efficacy and future CA.</p>","PeriodicalId":54378,"journal":{"name":"Eurointervention","volume":"21 12","pages":"e692-e703"},"PeriodicalIF":7.6,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12151166/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144303597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Guideline recommendations for QFR should be revisited: pros and cons. QFR的指南建议应该重新审视:利弊。
IF 7.6 1区 医学
Eurointervention Pub Date : 2025-06-16 DOI: 10.4244/EIJ-E-25-00009
William F Fearon, Simone Biscaglia
{"title":"Guideline recommendations for QFR should be revisited: pros and cons.","authors":"William F Fearon, Simone Biscaglia","doi":"10.4244/EIJ-E-25-00009","DOIUrl":"10.4244/EIJ-E-25-00009","url":null,"abstract":"","PeriodicalId":54378,"journal":{"name":"Eurointervention","volume":"21 12","pages":"e652-e654"},"PeriodicalIF":7.6,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12151161/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144303598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Letter: Completeness or complexity? A nuanced reflection on multivessel revascularisation. 信:完整还是复杂?对多血管重建的细致反映。
IF 7.6 1区 医学
Eurointervention Pub Date : 2025-06-16 DOI: 10.4244/EIJ-D-25-00197
Alessandro Sticchi, Giuseppe Biondi-Zoccai
{"title":"Letter: Completeness or complexity? A nuanced reflection on multivessel revascularisation.","authors":"Alessandro Sticchi, Giuseppe Biondi-Zoccai","doi":"10.4244/EIJ-D-25-00197","DOIUrl":"10.4244/EIJ-D-25-00197","url":null,"abstract":"","PeriodicalId":54378,"journal":{"name":"Eurointervention","volume":"21 12","pages":"e711-e712"},"PeriodicalIF":7.6,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12151160/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144303599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Predictors of pacemaker implantation in aortic regurgitation patients treated with a dedicated transcatheter heart valve. 经专用经导管心脏瓣膜治疗的主动脉瓣返流患者心脏起搏器植入的预测因素。
IF 7.6 1区 医学
Eurointervention Pub Date : 2025-06-16 DOI: 10.4244/EIJ-D-24-01117
Hendrik Wienemann, Martin Geyer, Malte Stukenberg, Sara Waezsada, Kush P Patel, Elmar W Kuhn, Marc Adrian Rogmann, Duane S Pinto, Lenard Conradi, Sabine Bleiziffer, Stephan Baldus, Andreas Baumbach, Tanja K Rudolph, Matti Adam
{"title":"Predictors of pacemaker implantation in aortic regurgitation patients treated with a dedicated transcatheter heart valve.","authors":"Hendrik Wienemann, Martin Geyer, Malte Stukenberg, Sara Waezsada, Kush P Patel, Elmar W Kuhn, Marc Adrian Rogmann, Duane S Pinto, Lenard Conradi, Sabine Bleiziffer, Stephan Baldus, Andreas Baumbach, Tanja K Rudolph, Matti Adam","doi":"10.4244/EIJ-D-24-01117","DOIUrl":"10.4244/EIJ-D-24-01117","url":null,"abstract":"<p><strong>Background: </strong>The JenaValve Trilogy System (JVTS) is the only dedicated transcatheter heart valve system approved for treating patients with aortic regurgitation (AR). Recently, several studies have revealed high rates of permanent pacemaker implantation (PPI) exceeding 20% in patients with AR.</p><p><strong>Aims: </strong>The aim of this study was to evaluate the incidence and risk factors for new PPI after transcatheter aortic valve implantation (TAVI) with the JVTS.</p><p><strong>Methods: </strong>This retrospective multicentre registry included 141 patients without prior PPI who underwent transfemoral TAVI with the JVTS. Comparative analyses were performed regarding baseline and procedural parameters between patients with and without new PPI at discharge. Logistic regression models were fitted to identify predictors of PPI.</p><p><strong>Results: </strong>The median age of patients was 81 (interquartile range [IQR] 76-85) years, 41% were female, and the median European System for Cardiac Operative Risk Evaluation (EuroSCORE) II was 3.6% (IQR 2.0-6.4). All patients presented with ≥moderate AR. At discharge, 34 patients (24.1%) required a new PPI. Pre-existing first-degree atrioventricular block and right bundle branch block were identified as independent predictors of new PPI. Anatomical characteristics, including annular and left ventricular outflow tract perimeters, were not predictive. Procedural factors such as implantation depth and valve oversizing were also not statistically different between patients with or without new PPI.</p><p><strong>Conclusions: </strong>Overall, 24.1% of patients undergoing TAVI with the JVTS required a new PPI. While rates of new PPI were strongly associated with pre-existing first-degree atrioventricular block and right bundle branch block using the JVTS, no modifiable risk factors were identified.</p>","PeriodicalId":54378,"journal":{"name":"Eurointervention","volume":"21 12","pages":"e681-e691"},"PeriodicalIF":7.6,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12151165/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144303601","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信